Evommune Reports Positive Phase 2a Data for EVO301 in Atopic Dermatitis

Evommune announced positive Phase 2a data for its EVO301 drug candidate in treating atopic dermatitis. The results showed a clear therapeutic signal, a favorable safety profile, and biomarker evidence of broad anti-inflammatory activity.